Glycocalyx is a network of proteoglycans with glycosaminoglycan side chains and is an important component of the eukaryotic cell surface. In the eyes, glycocalyx is expressed on corneal and ...

A recent study from the University of Bristol offers new hope for people with diabetes, who are at a high risk of kidney ...

Diabetes doesn’t just impact blood sugar; it often leads to serious kidney issues, too. In fact, about 40% of people with diabetes develop a condition known as diabetic kidney disease. In the UK, ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.

Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced that it has been awarded a $2.2 million contract from the Joint Warfighter ...

Synedgen’s Multivalent Innate Immune Signaling Target (MIIST) platform targets receptors in the glycocalyx, a key to human innate immunity. Historically an underappreciated target in drug development, ...

MIIST305, derived from this platform, is a non-systemic therapeutic that modulates innate immune receptor responses and targets the anionic glycocalyx at the gastrointestinal cell surface to ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts. Export articles to Mendeley Get article recommendations from ACS based on references in your ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

MIIST305, derived from this platform, is a non-systemic therapeutic that modulates innate immune receptor responses and targets the anionic glycocalyx at the gastrointestinal cell surface to repair ...